Market Overview:
The global long acting beta agonist market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of respiratory diseases, rising geriatric population, and growing demand for long-acting beta agonists drugs. Based on type, the global long acting beta agonist market is segmented into liquid, tablet, and others (inhalers and nebulizers). The liquid segment is expected to account for the largest share of the global long acting beta agonist market in 2018. This can be attributed to factors such as ease of use and high efficacy offered by these drugs. Based on application, the global long acting beta agonist market is segmented into hospitals, clinics, ambulatory surgical center (ASCs), and others (research institutes and home care settings). The hospitals segment accounted for the largest share of the global long acting beta agonist market in 2017. This can be attributed to factors such as increasing number of hospital admissions owing to respiratory diseases and growing demand for technologically advanced therapies such as inhalers and nebulizers.
Product Definition:
A long-acting beta agonist (LABA) is a bronchodilator medication prescribed to relieve asthma symptoms. It is a type of long-term controller medication used to prevent asthma attacks. LABA medications work by relaxing the muscles around the airways, making it easier to breathe.
Liquid:
The global long-acting beta agonist market is expected to witness significant growth over the forecast period. The factors that propel the growth of this market include increasing prevalence of chronic diseases such as asthma, COPD and diabetes coupled with rising demand for efficient drugs due to growing geriatric population base.
Tablet:
A tablet is a small dosage form of medicine used to treat or prevent diseases. They are available in different forms such as capsules, tablets, and powders. Tablets are easy to swallow and provide the required amount of drug at one time. The size and shape make them more appealing than other dosage forms such as capsules which have large volumes that require separate measures for each dose.
Application Insights:
The clinics, ambulatory surgical centers, and hospitals application segment dominated the global market in 2017. The key factors contributing to this growth include increasing number of gym-based SABAs for weight loss and maintenance as well as growing awareness about these devices among healthcare professionals. Furthermore, rising prevalence of obesity is also driving the demand for SABAs in this segment.
Clinics held a major share in terms of revenue as well as volume in 2017 owing to an increase in the adoption of these devices by patients seeking non-surgical solutions for weight loss or management. Moreover, clinics are able to provide sessions at a more convenient time due to their open hours compared with hospitals which leads to increased penetration rate among obese patients who seek professional help regarding weight reduction or management at their respective homes or workplaces.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high demand for beta agonists, and favorable reimbursement scenario. The U.S., which is a major consumer of long acting beta agonist medicines, accounted for more than 80% share in North America owing to increasing use of these products due to rising incidence of asthma and COPD coupled with growing awareness about their benefits among patients.
Growth Factors:
- Increasing prevalence of asthma and other respiratory diseases: The global Long Acting Beta Agonist market is expected to grow at a CAGR of 5.5% during the forecast period owing to the increasing prevalence of asthma and other respiratory diseases.
- Technological advancements in Long Acting Beta Agonist products: The technological advancements in Long Acting Beta Agonist products are expected to drive the growth of this market during the forecast period. For instance, Inhaled corticosteroids (ICS) are now available as pressurized metered-dose inhalers (pMDIs) with built-in spacers that make it easier for patients to use them correctly and help deliver more drug to their lungs than hand-held dry powder inhalers (DPIs). This is likely to increase patient compliance rates and propel market growth over the forecast period.
- Growing geriatric population: The global geriatric population is growing at a rapid pace, which is anticipated to fuel demand for Long Acting Beta Agonists over the next few years. Elderly people are more susceptible to respiratory problems such as asthma, which can be effectively treated with long acting beta agonists drugs therapies .Thus, rising geriatric population will create lucrative opportunities for players operating in this market over the forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
Long Acting Beta Agonist Market Research Report
By Type
Liquid, Tablet, Long Acting Beta Agonis
By Application
Hospitals, Clinics, Ambulatory Surgical Center, Others
By Companies
Sumitomo Dainippon Pharma, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim International, Mylan, Teva, Merck, Long Acting Beta Agonis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Long Acting Beta Agonist Market Report Segments:
The global Long Acting Beta Agonist market is segmented on the basis of:
Types
Liquid, Tablet, Long Acting Beta Agonis
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Ambulatory Surgical Center, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sumitomo Dainippon Pharma
- AstraZeneca
- GlaxoSmithKline
- Boehringer Ingelheim International
- Mylan
- Teva
- Merck
- Long Acting Beta Agonis
Highlights of The Long Acting Beta Agonist Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Liquid
- Tablet
- Long Acting Beta Agonis
- By Application:
- Hospitals
- Clinics
- Ambulatory Surgical Center
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Long Acting Beta Agonist Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A long-acting beta agonist is a type of medication that helps to reduce inflammation and pain. These medications are often prescribed to people who have chronic conditions, such as arthritis, back pain, or Crohn's disease.
Some of the key players operating in the long acting beta agonist market are Sumitomo Dainippon Pharma, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim International, Mylan, Teva, Merck, Long Acting Beta Agonis.
The long acting beta agonist market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Long Acting Beta Agonist Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Long Acting Beta Agonist Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Long Acting Beta Agonist Market - Supply Chain
4.5. Global Long Acting Beta Agonist Market Forecast
4.5.1. Long Acting Beta Agonist Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Long Acting Beta Agonist Market Size (000 Units) and Y-o-Y Growth
4.5.3. Long Acting Beta Agonist Market Absolute $ Opportunity
5. Global Long Acting Beta Agonist Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Long Acting Beta Agonist Market Size and Volume Forecast by Type
5.3.1. Liquid
5.3.2. Tablet
5.3.3. Long Acting Beta Agonis
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Long Acting Beta Agonist Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Long Acting Beta Agonist Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Ambulatory Surgical Center
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Long Acting Beta Agonist Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Long Acting Beta Agonist Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Long Acting Beta Agonist Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Long Acting Beta Agonist Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Long Acting Beta Agonist Demand Share Forecast, 2019-2026
9. North America Long Acting Beta Agonist Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Long Acting Beta Agonist Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Long Acting Beta Agonist Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Ambulatory Surgical Center
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Long Acting Beta Agonist Market Size and Volume Forecast by Type
9.7.1. Liquid
9.7.2. Tablet
9.7.3. Long Acting Beta Agonis
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Long Acting Beta Agonist Demand Share Forecast, 2019-2026
10. Latin America Long Acting Beta Agonist Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Long Acting Beta Agonist Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Long Acting Beta Agonist Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Ambulatory Surgical Center
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Long Acting Beta Agonist Market Size and Volume Forecast by Type
10.7.1. Liquid
10.7.2. Tablet
10.7.3. Long Acting Beta Agonis
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Long Acting Beta Agonist Demand Share Forecast, 2019-2026
11. Europe Long Acting Beta Agonist Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Long Acting Beta Agonist Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Long Acting Beta Agonist Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Ambulatory Surgical Center
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Long Acting Beta Agonist Market Size and Volume Forecast by Type
11.7.1. Liquid
11.7.2. Tablet
11.7.3. Long Acting Beta Agonis
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Long Acting Beta Agonist Demand Share, 2019-2026
12. Asia Pacific Long Acting Beta Agonist Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Long Acting Beta Agonist Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Long Acting Beta Agonist Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Ambulatory Surgical Center
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Long Acting Beta Agonist Market Size and Volume Forecast by Type
12.7.1. Liquid
12.7.2. Tablet
12.7.3. Long Acting Beta Agonis
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Long Acting Beta Agonist Demand Share, 2019-2026
13. Middle East & Africa Long Acting Beta Agonist Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Long Acting Beta Agonist Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Long Acting Beta Agonist Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Ambulatory Surgical Center
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Long Acting Beta Agonist Market Size and Volume Forecast by Type
13.7.1. Liquid
13.7.2. Tablet
13.7.3. Long Acting Beta Agonis
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Long Acting Beta Agonist Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Long Acting Beta Agonist Market: Market Share Analysis
14.2. Long Acting Beta Agonist Distributors and Customers
14.3. Long Acting Beta Agonist Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sumitomo Dainippon Pharma
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GlaxoSmithKline
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Boehringer Ingelheim International
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Mylan
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Teva
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Merck
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Long Acting Beta Agonis
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
